PMID- 27516366
OWN - NLM
STAT- MEDLINE
DCOM- 20170929
LR  - 20181202
IS  - 1526-4637 (Electronic)
IS  - 1526-2375 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Jan 1
TI  - Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of 
      Moderate to Severe Pain: A Systematic Review and Meta-Analysis.
PG  - 14-24
LID - 10.1093/pm/pnw154 [doi]
AB  - OBJECTIVE: To assess the efficacy and safety of tapentadol IR for moderate to 
      severe pain compared to oxycodone IR. METHODS: A search was carried out up to 
      July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to 
      placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were 
      pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence 
      interval (CI). RESULTS: Nine RCTs (n = 3,961) were analyzed. In this 
      meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant 
      improvements in moderate to severe pain relief on the sum of pain intensity 
      difference over 48 hours (SPID 48 ) scores ( P  <   0.00001 or P  =   0.01). No 
      statistically significant difference among all three doses of tapentadol IR and 
      oxycodone HCL IR 10 mg on both SPID 48 and total pain relief over 48 hours 
      (TOTPAR 48 ) scores (all P  >   0.05) was found. Compared with tapentadol IR 
      50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to 
      severe pain relief based on both SPID 48 and TOTPAR 48 scores (all P  <   0.05). 
      For total adverse events (AEs) incidence, tapentadol IR 50 and 75 mg were 
      significantly lower than oxycodone HCL IR 10 mg. Incidence of nausea and 
      constipation were significantly lower with either tapentadol IR 50 or 75 mg 
      compared with oxycodone HCL IR 10 mg (all P  <   0.05). CONCLUSIONS: Tapentadol 
      IR 75 mg might be an optimal dose for moderate to severe pain control with fewer 
      side effects. All three doses of tapentadol IR could provide comparable efficacy 
      to oxycodone HCL IR 10 mg.
CI  - (c) 2016 American Academy of Pain Medicine. All rights reserved. For permissions, 
      please e-mail: journals.permissions@oup.com
FAU - Xiao, Jing-Ping
AU  - Xiao JP
AD  - Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, 
      Luzhou, Sichuan Province, China.
FAU - Li, Ai-Ling
AU  - Li AL
AD  - Evidence Based Medicine Center of Luzhou Medical College, Luzhou, Sichuan 
      Province, China.
FAU - Feng, Bi-Min
AU  - Feng BM
AD  - Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, 
      Luzhou, Sichuan Province, China.
FAU - Ye, Yun
AU  - Ye Y
AD  - Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, 
      Luzhou, Sichuan Province, China.
FAU - Wang, Guo-Jun
AU  - Wang GJ
AD  - Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, 
      Luzhou, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Pain Med
JT  - Pain medicine (Malden, Mass.)
JID - 100894201
RN  - 0 (Analgesics)
RN  - 0 (Phenols)
RN  - H8A007M585 (Tapentadol)
SB  - IM
MH  - Analgesics/*therapeutic use
MH  - Humans
MH  - Pain/*drug therapy
MH  - Phenols/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Tapentadol
OTO - NOTNLM
OT  - Moderate to Severe Pain
OT  - Systematic Review
OT  - Tapentadol Immediate Release
EDAT- 2016/08/16 06:00
MHDA- 2017/09/30 06:00
CRDT- 2016/08/13 06:00
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/09/30 06:00 [medline]
PHST- 2016/08/13 06:00 [entrez]
AID - pnw154 [pii]
AID - 10.1093/pm/pnw154 [doi]
PST - ppublish
SO  - Pain Med. 2017 Jan 1;18(1):14-24. doi: 10.1093/pm/pnw154.